Connect Medical Value Scores ￥10M in Series A Financing

(VCBeat) Apr. 07, 2021 -- Hangzhou Yongliu Technology Co., Ltd. ("Connect Medical Value"), a medical technology and professional service platform company, today announced the closing of a Series A financing of tens of millions of yuan. This round was led by Sequoia Capital China, with participation from Hangzhou Wanlun Shangde and the angel round investor Marathon Venture Partners. 

According to Connect Medical Value, the fresh round of funding will be used towards the development of a doctor-patient service platform, the building of the professional service system, team development and market expansion.

Case management and digital therapy is one of the hottest topics in the digital medical industry. The industry defines digital therapy as providing patients with evidence-based therapeutic interventions in the form of software to prevent, manage, or treat disease. Digital therapy products can be used alone or in conjunction with drugs, devices, or other treatments. These products combine the latest advances in evidence-based diagnosis and treatment for specific diseases, digital technologies, and data security, and are reviewed and approved by government regulators in accordance with relevant policies.

With the rapid development of innovative technologies and business models, 2020, as the first year of the development of integrated case management and digital therapy in China, is a new era of industrial development. Under such a great trend, emerging companies with roots in segmented disease fields and professional service management and digital application capabilities will have the opportunity to make more contributions to the innovation and development of China's medical industry.

As a practitioner in the innovation of science and technology development, Connect Medical Value is engaged in skin disease treatment based on scientific methods of disease diagnosis and treatment to create individualized solutions for patients. The company has cooperated with medical experts, doctors and partners in the construction and development of skin disease case management systems and high-value products, to support more doctors, benefit more patients, and create win-win development.

Sequoia Capital China is a VC firm focused on seed-stage, mid-stage, late-stage, and growth investments in the fintech sector.

Formed in September 2005, Sequoia Capital China has an impressive and diverse portfolio comprising about 300 dynamic companies that deliver high returns on investment using differentiated technologies and innovative business models, including Alibaba, VIPshop.com, Sina.com, Didi, JD.com, Ourpalm, Qihoo 360, Jumei, Momo, and so on.

Founded in 2016, MVP is a leading early-stage venture capital firm focused on healthcare with offices in Beijing, Shanghai, Suzhou and Hong Kong. MVP currently manages both US Dollar and RMB funds. MVP backs outstanding entrepreneurs in China's healthcare technology industries at the beginning of their entrepreneurial journey.